Prognosis
Teva CEO Says Drugmaker Will Fight U.S. Price-Fixing Charges
- Drugmaker indicted by U.S. prosecutors after yearslong probe
- Top executive says Teva’s operations will not be impacted
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd.’s chief executive officer said settlement talks with U.S. prosecutors failed after the Department of Justice demanded the generic-drug maker admit to allegations that could increase its exposure in other litigation.
“It’s hard to admit to a crime you didn’t commit,” CEO Kare Schultz said in an interview on Wednesday. “When it has significant collateral consequences for other legal situations occurring at the same time, it becomes even more difficult.”